Copyright
©The Author(s) 2024.
World J Exp Med. Dec 20, 2024; 14(4): 98543
Published online Dec 20, 2024. doi: 10.5493/wjem.v14.i4.98543
Published online Dec 20, 2024. doi: 10.5493/wjem.v14.i4.98543
Table 1 Baseline characteristics of included studies
| Ref. | Study design | Age (years) | Total patients (n) | Males/females | Statin users | Non-users | Cirrhosis | No cirrhosis | Follow-up (years) |
| Zou et al[51] | Cohort | 52.1 ± 14.7 | 272430 | 126804/145626 | 73384 | 199046 | 34257 | 238173 | 727390 person-year |
| Pinyopornpanish et al[50] | Cohort | 59 ± 10.4 | 1072 | 432/640 | 440 | 632 | 950 | 122 | 4326 person-year |
| German et al[49] | Case-control | 64.3 ± 13.1 | 102 | 66/36 | 40 | 62 | 93 | 9 | Not applicable |
| Lee et al[48] | Cohort | 52.7 (41.6-64.4) | 18080 | 9502/8578 | 6382 | 11698 | 0 | 18080 | 6.32 (3.04-10.10) |
- Citation: Tarar ZI, Farooq U, Inayat F, Basida SD, Ibrahim F, Gandhi M, Nawaz G, Afzal A, Chaudhary AJ, Kamal F, Ali AH, Ghouri YA. Statins decrease the risk of hepatocellular carcinoma in metabolic dysfunction-associated steatotic liver disease: A systematic review and meta-analysis. World J Exp Med 2024; 14(4): 98543
- URL: https://www.wjgnet.com/2220-315x/full/v14/i4/98543.htm
- DOI: https://dx.doi.org/10.5493/wjem.v14.i4.98543